📊 NUWE Key Takeaways
Is Nuwellis, Inc. (NUWE) a Good Investment?
Nuwellis is a cash-burning medical device company with declining revenue, operating losses consuming 192% of revenue, and only 8 months of cash runway at current burn rates. Despite healthy 70% gross margins indicating viable product economics, the company faces existential risk without near-term profitability achievement or significant capital infusion.
Fundamentals show a shrinking top line, deeply negative margins, and severe cash burn with only $1.08M in cash against -$10.9M FCF, creating acute liquidity and dilution risk. While gross margin is strong at 62%, the company lacks scale and posts substantial operating losses and negative interest coverage. Without a rapid turnaround in revenue and operating efficiency or new capital, financial sustainability is doubtful.
Why Buy Nuwellis, Inc. Stock? NUWE Key Strengths
- Strong gross margin of 70.1% indicates underlying product viability and pricing power
- Moderate leverage (0.74x Debt/Equity) provides some financial flexibility
- Asset-light model with minimal capex requirements ($30K) reduces capital intensity
- High gross margin (62%) suggests product value
- Current ratio above 1.5 provides limited cushion
- Low capex needs support scalability if demand improves
NUWE Stock Risks: Nuwellis, Inc. Investment Risks
- Negative operating cash flow of -$3.1M with only $2.1M cash = ~8 months runway before insolvency
- Revenue declining 5.4% YoY while operating losses exceed revenue by 2x, indicating failed commercialization
- Operating margin of -190% with -$4.6M operating loss on $2.4M revenue shows inability to control costs or scale efficiently
- Negative ROE (-170.7%) and ROA (-65.2%) demonstrate severe value destruction
- Interest coverage of -9.1x reflects inability to service debt from operations
- Going-concern/liquidity risk given minimal cash vs. burn
- Sustained operating losses and negative interest coverage (-22x)
- Revenue decline and subscale operations limit operating leverage
Key Metrics to Watch
- Quarterly revenue trend and return to growth trajectory
- Operating expense reduction and path to positive operating income
- Cash burn rate and months of cash runway remaining
- Operating cash flow inflection to positive
- Capital raise announcements or partnership developments indicating survival strategy
- Quarterly operating cash burn and cash balance
- Revenue growth and operating margin improvement
Nuwellis, Inc. (NUWE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Nuwellis, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
NUWE Profit Margin, ROE & Profitability Analysis
NUWE vs Healthcare Sector: How Nuwellis, Inc. Compares
How Nuwellis, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nuwellis, Inc. Stock Overvalued? NUWE Valuation Analysis 2026
Based on fundamental analysis, Nuwellis, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nuwellis, Inc. Balance Sheet: NUWE Debt, Cash & Liquidity
NUWE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nuwellis, Inc.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-353.30 indicates the company is currently unprofitable.
NUWE Revenue Growth, EPS Growth & YoY Performance
NUWE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.9M | -$3.0M | $-2.19 |
| Q3 2025 | $2.2M | $468.0K | $0.56 |
| Q2 2025 | $1.7M | -$3.0M | $-60.99 |
| Q1 2025 | $1.9M | -$3.0M | $-0.69 |
| Q3 2024 | $2.4M | $2.4M | $1.74 |
| Q2 2024 | $2.1M | -$4.3M | $-18.85 |
| Q1 2024 | $1.8M | -$4.3M | $-0.60 |
| Q3 2023 | $2.1M | -$3.4M | $-1.81 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nuwellis, Inc. Dividends, Buybacks & Capital Allocation
NUWE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nuwellis, Inc. (CIK: 0001506492)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUWE
What is the AI rating for NUWE?
Nuwellis, Inc. (NUWE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUWE's key strengths?
Claude: Strong gross margin of 70.1% indicates underlying product viability and pricing power. Moderate leverage (0.74x Debt/Equity) provides some financial flexibility. ChatGPT: High gross margin (62%) suggests product value. Current ratio above 1.5 provides limited cushion.
What are the risks of investing in NUWE?
Claude: Negative operating cash flow of -$3.1M with only $2.1M cash = ~8 months runway before insolvency. Revenue declining 5.4% YoY while operating losses exceed revenue by 2x, indicating failed commercialization. ChatGPT: Going-concern/liquidity risk given minimal cash vs. burn. Sustained operating losses and negative interest coverage (-22x).
What is NUWE's revenue and growth?
Nuwellis, Inc. reported revenue of $2.4M.
Does NUWE pay dividends?
Nuwellis, Inc. does not currently pay dividends.
Where can I find NUWE SEC filings?
Official SEC filings for Nuwellis, Inc. (CIK: 0001506492) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUWE's EPS?
Nuwellis, Inc. has a diluted EPS of $-2.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUWE a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Nuwellis, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUWE stock overvalued or undervalued?
Valuation metrics for NUWE: ROE of -170.7% (sector avg: 15%), net margin of -189.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUWE stock in 2026?
Our dual AI analysis gives Nuwellis, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUWE's free cash flow?
Nuwellis, Inc.'s operating cash flow is $-3.1M, with capital expenditures of $30.0K. FCF margin is -130.8%.
How does NUWE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -189.0% (avg: 12%), ROE -170.7% (avg: 15%), current ratio 1.56 (avg: 2).